/ALIM

ALIM Stock - Alimera Sciences, Inc.

Q: What is the analyst price target for ALIM?

Analyst price target information is not currently available for ALIM.

Q: What is ALIM's market cap?

Market capitalization information is not currently available for ALIM.

Healthcare|Drug Manufacturers - Specialty & Generic|NASDAQ

$5.54-0.18%

$0.01 (-0.18%) • Sep 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+28.7%upside

Target: $7.13

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ALIM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.25

52W High$5.65

52W Low$2.61

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$80.75M	$54.13M	$59.03M	$50.82M	$53.94M
Gross Profit	$61.17M	$46.15M	$52.00M	$43.88M	$47.32M
Gross Margin	75.7%	85.3%	88.1%	86.3%	87.7%
Operating Income	$-1,932,000	$-11,640,000	$-201,000	$-501,000	$-5,274,000
Net Income	$-20,132,000	$-18,107,000	$-4,372,000	$-5,339,000	$-10,443,000
Net Margin	-24.9%	-33.5%	-7.4%	-10.5%	-19.4%
EPS	$-0.79	$-2.59	$-0.66	$-1.04	$-2.19

Company Overview

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

67%

Hold / Neutral

33%

Sell / Underperform

Analyst Consensus🟡 Mixed

2 Bullish1 Neutral/Bearish

Price Targets

Average Target

↑ 62.5% Upside

Now

Low

Average

$10

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
June 25th 2024	H.C. Wainwright	Downgrade	Neutral	-
March 25th 2024	Maxim Group	Initiation	Buy	$10
October 30th 2023	Alliance Global Partners	Upgrade	Buy	$8

Earnings History & Surprises

ALIM

Beat Rate

30%

Last 20 quarters

Avg Surprise

-100.7%

EPS vs Estimate

Beats / Misses

6/14

Last 12 quarters

Latest EPS

$-0.06

Q4 2024

EPS Surprise History

Q1 23

-92.9%

$-0.54vs$-0.28

Q2 23

-22.4%

$-0.71vs$-0.58

Q3 23

-833.3%

$-0.44vs$0.06

Q4 23

+85.4%

$-0.06vs$-0.41

Q1 24

-450.0%

$-0.07vs$0.02

Q2 24

-111.8%

$-0.12vs$-0.06

Q3 24

-63.6%

$-0.06vs$-0.04

Q4 24

-500.0%

$-0.06vs$-0.01

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2024	Oct 24, 2024	$-0.01	$-0.06	-500.0%	✗ MISS
Q3 2024	Aug 6, 2024	$-0.04	$-0.06	-63.6%	✗ MISS
Q2 2024	May 14, 2024	$-0.06	$-0.12	-111.8%	✗ MISS
Q1 2024	Mar 7, 2024	$0.02	$-0.07	-450.0%	✗ MISS
Q4 2023	Oct 26, 2023	$-0.41	$-0.06	+85.4%	✓ BEAT
Q3 2023	Aug 10, 2023	$0.06	$-0.44	-833.3%	✗ MISS
Q2 2023	May 15, 2023	$-0.58	$-0.71	-22.4%	✗ MISS
Q1 2023	Mar 31, 2023	$-0.28	$-0.54	-92.9%	✗ MISS
Q4 2022	Nov 14, 2022	$-0.37	$-0.75	-102.7%	✗ MISS
Q3 2022	Jul 27, 2022	$-0.61	$-0.45	+26.2%	✓ BEAT
Q2 2022	May 9, 2022	$-0.67	$-0.85	-26.9%	✗ MISS
Q1 2022	Feb 24, 2022	$-0.38	$-0.59	-55.3%	✗ MISS
Q4 2021	Oct 28, 2021	$-0.52	$-0.60	-15.4%	✗ MISS
Q3 2021	Aug 13, 2021	$1.25	$0.76	-39.2%	✗ MISS
Q2 2021	Apr 28, 2021	$-0.50	$-0.63	-26.0%	✗ MISS
Q1 2021	Feb 24, 2021	$-0.09	$-0.18	-100.0%	✗ MISS
Q4 2020	Oct 28, 2020	$-0.49	$-0.12	+75.5%	✓ BEAT
Q3 2020	Jul 29, 2020	$-2.14	$-0.51	+76.2%	✓ BEAT
Q2 2020	Apr 29, 2020	$-0.43	$-0.24	+44.2%	✓ BEAT
Q1 2020	Feb 26, 2020	$-0.45	$0.08	+117.8%	✓ BEAT

Frequently Asked Questions about ALIM

What is ALIM's current stock price?

Alimera Sciences, Inc. (ALIM) is currently trading at $5.54 per share. The stock has moved -0.18% today.

What is the analyst price target for ALIM?

The average analyst price target for ALIM is $7.13, based on 1 analyst.

What sector is Alimera Sciences, Inc. in?

Alimera Sciences, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.

What is ALIM's market cap?

Alimera Sciences, Inc. has a market capitalization of $0.30 billion, making it a small-cap company.

Does ALIM pay dividends?

No, Alimera Sciences, Inc. does not currently pay a dividend to shareholders.